Cerebellum’s Haemonetics HAE Stock Holding History

Cerebellum’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,384	Closed	-$239K	–	481
2018 Q4	$239K	Buy	+2,384	New	+$250K	0.17%	242

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Cerebellum's HAE Position: Q1 2019 in Review

Cerebellum sold out of Haemonetics (HAE) in Q1 2019, closing a stake of 2,384 shares — an estimated $239K sold.

Cerebellum first reported a position in HAE in Q4 2018 and held it in 1 quarter. The position peaked at $239K in Q4 2018. 260 funds tracked by Wall St. Rank hold HAE as of Q1 2019.

Cerebellum reported no remaining Haemonetics position as of Q1 2019 after selling out during the quarter.
Cerebellum sold 2,384 Haemonetics shares in Q1 2019, an estimated $239K.
Cerebellum first reported a position in Haemonetics in Q4 2018 and held it in 1 quarter.
Cerebellum's Haemonetics position peaked at $239K in Q4 2018.
260 funds tracked by Wall St. Rank held Haemonetics as of Q1 2019.

Based on Cerebellum's 13F filing for Q1 2019, filed 21 May 2019.